QR Pharma, Inc., a Berwyn (Montgomery County), PA-based specialty pharmaceutical company, has received $110k follow-on investment from Ben Franklin Technology Partners of Southeastern Pennsylvania (BFTP/SEP).
Ben Franklin previously invested $500,000 in QR Pharma, which aims to develop novel treatments for Alzheimer’s, Parkinson’s and other neurodegenerative disorders. Its Posiphen®, currently in clinical development, targets early stage Alzheimer’s and Parkinson’s in order to stop or slow the progression of the disease. The company is also advancing BNC, which targets late stage AD to stabilize the decline.
QR Pharma is also led by Founder, CEO & President Maria Maccecchini, Ph.D., and COO John Bennett.